All News

Ada Stewart, MD, reviews current guidelines, addresses patient hesitancy, and explains how HPV self-collection tests may expand screening options in primary care.

The novel IL-22 blocker was associated with improvements in EASI as early as week 1 for lower doses and week 2 for the highest dose, compared with placebo.

EADV 2025: New phase 3 data reveal delgocitinib cream's efficacy for chronic hand eczema in adolescents, confirming its safety profile in adults.

The updated prescribing information includes phase 3b BATURA trial results showing a 46% reduction in severe exacerbations in mild asthma vs albuterol.

In children aged 10 to <18 with T2D inadequately controlled on standard of care treatment, tirzepatide reduced HbA1c by an average of 2.2% and reduced BMI as well.

Atypical causes of MI in women included spontaneous coronary artery dissection, which was 6 times more common in women than in men, a Mayo Clinic study found.

Regardless of decisions made during the ACIP meeting, health insurance plans will continue to cover shots recommended by ACIP as of Sept 1.

Among 180+ active AD trials, 15 biological targets span traditional Aβ and tau proteins as well as new pathways in brain metabolism, neuroinflammation, and synaptic health.

This week’s podcast episode covers cervical cancer disparities, HPV awareness, depression risk, pharmacy CRC screening, and semaglutide approval for MASH.

EASD 2025. A new oral GLP-1 receptor agonist, orforglipron, shows promise for significant weight loss and improved cardiometabolic health in adults with obesity.

EASD 2025: After initiating treatment with semaglutide, the number of people who reported experiencing constant thoughts about food throughout the day declined by 46%.

The investigational ShiraTronics Migraine Therapy System delivered an average of 9.6 migraine-free days per month, reduced rescue medication use, and improved QOL.

In honor of Gynecologic Cancer Awareness Month, Ada Stewart, MD, emphasizes the vital role of primary care in ensuring every eligible woman receives cervical cancer screening and follow-up care.

EASD 2025: Findings from a subanalysis of the REDEFINE 1 phase 3 trial support Novo Nordisk's plan to advance cagrilintide into a dedicated clinical program this year.

Real-time continuous glucose monitoring significantly enhances glycemic control in gestational diabetes, reducing risks for large newborns compared to traditional methods.

EASD 2025: The risk of developing the 4 primary subtypes of T2D was increased by as much as 3-fold and was not dependent on duration of smoking behavior.

Your daily dose of the clinical news you may have missed.

Most parents support childhood vaccines such as MMR and polio, but skepticism about seasonal and newer shots persists, along with distrust of federal agencies.